Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Neurogene Inc(NGNE)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NGNE
09/16/2026: NGNE (2-star) is a SELL. SELL for 4 days. Simulated Profits (-10.02%). Updated daily EoD!
Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases using its proprietary EXACT gene-regulation platform. Its primary investment story centers on the potential of NGN-401 and NGN-101 to address significant unmet medical needs in conditions like Rett syndrome and Batten disease. Key strengths include specialized technical expertise and a focus on precision delivery, though the company remains pre-revenue and faces high execution risk. Prospective investors should monitor clinical trial progress, as success could drive substantial value, whereas failures pose existential risks. This stock is best suited for speculative growth investors comfortable with the high volatility inherent in early-stage biotechnology.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk, high-reward stock suitable only for those seeking exposure to early-stage gene therapy clinical progress. |
| Momentum investor | Mixed fit | Momentum is highly dependent on clinical trial announcements; a strong signal would require positive, market-moving data readouts. |
| Value investor | Weak fit | As a pre-revenue biotechnology company, traditional value metrics like P/E ratios are not applicable. |
| Dividend investor | Weak fit | The company has no revenue and reinvests all capital into research, making it unsuitable for income-focused investors. |
| Low-risk investor | Weak fit | High volatility and the existential risk of clinical trial failures make this inappropriate for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is highly sensitive to news flow and clinical developments, leading to significant price swings. |
| Valuation risk | Medium / high | Without commercial products, valuation is speculative and heavily dependent on analyst estimates of future success. |
| Competition risk (gene therapy developers) | High | Large competitors with more resources can move faster or develop superior delivery platforms. |
| Business quality | Medium | While the platform is novel, the company is unproven as a commercial enterprise. |
| Dividend income | Low / none | There is no dividend income and none expected in the foreseeable future. |
| Execution risk | High | The company faces the complex, high-risk challenge of conducting successful clinical trials and meeting regulatory standards. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -48.52% | Avg. Invested days 23 | Today’s Advisory SELL |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 693.79M USD | Price to earnings Ratio - | 1Y Target Price 80.43 |
Price to earnings Ratio - | 1Y Target Price 80.43 | ||
Volume (30-day avg) 209.8K shares | Beta 1.96 | 52 Weeks Range 15.93 - 43.66 | Updated Date 09/17/2026 |
52 Weeks Range 15.93 - 43.66 | Updated Date 09/17/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.19 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical-Stage Biotechnology | Research and development of AAV-based gene therapies for rare neurological diseases. | The company currently makes no money; it burns cash to research products it hopes to sell in the future. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 457.34M | Price to Sales(TTM) 438.73 |
Enterprise Value 457.34M | Price to Sales(TTM) 438.73 | ||
Enterprise Value to Revenue 480.94 | Enterprise Value to EBITDA -8.02 | Shares Outstanding 20.01M | Shares Floating 11.33M |
Shares Outstanding 20.01M | Shares Floating 11.33M | ||
Percent Insiders 6.98 | Percent Institutions 88.92 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Neurogene Inc
Exchange NASDAQ | Headquarters New York, NY, United States | ||
IPO Launch date 2014-03-07 | Founder, Executive Chair & CEO Dr. Rachel L. McMinn Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 131 | Website https://www.neurogene.com |
Full time employees 131 | Website https://www.neurogene.com | ||
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.